RÉSUMÉ
The efficacy of morbid obesity therapy at present remains rather low. Bariatric surgery is one of the most efficient methods for the treatment. Safety, efficacy and favourable results of the surgery are provided only after thorough examination of the patients.
Sujet(s)
Chirurgie bariatrique/effets indésirables , Syndrome de Cushing/étiologie , Obésité morbide/chirurgie , Complications postopératoires , Femelle , Humains , Adulte d'âge moyenRÉSUMÉ
Nineteen patients with bronchopulmonary infection and myasthenia gravis were enrolled in the study. The microbiological analysis of the specimens of phlegm and bronchial secretion revealed both grampositive and gramnegative bacteria. All the isolates were susceptible to the antibiotic used (cefoperazone/sulbactam). Intravenous immunoglobulins (IvIgs) were used to increase the treatment efficacy, to opsonize the infection foci and to decrease the hospitalization terms. The antibiotic therapy and simultaneous use of intravenous immunoglobulins provided higher clinical efficacy in 16 out of 19 patients (84.2%).
Sujet(s)
Antibactériens/usage thérapeutique , Bronchopneumonie/traitement médicamenteux , Céfopérazone/usage thérapeutique , Immunoglobulines par voie veineuse/usage thérapeutique , Myasthénie/traitement médicamenteux , Pneumopathie bactérienne/traitement médicamenteux , Sulbactam/usage thérapeutique , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Bronchopneumonie/complications , Bronchopneumonie/immunologie , Bronchopneumonie/microbiologie , Association de médicaments , Femelle , Bactéries à Gram négatif/effets des médicaments et des substances chimiques , Bactéries à Gram négatif/croissance et développement , Bactéries à Gram positif/effets des médicaments et des substances chimiques , Bactéries à Gram positif/croissance et développement , Humains , Mâle , Adulte d'âge moyen , Myasthénie/complications , Myasthénie/immunologie , Myasthénie/microbiologie , Pneumopathie bactérienne/complications , Pneumopathie bactérienne/immunologie , Pneumopathie bactérienne/microbiologie , Résultat thérapeutiqueRÉSUMÉ
The results of the clinico-microbiological investigation of the levofloxacin efficacy in the treatment of 38 patients with respiratory infections or various pyo-inflammatory lesions are presented. The positive results were stated in 29 (76.3%) patients. No adverse reactions were observed.
Sujet(s)
Antibactériens/usage thérapeutique , Bronchite/traitement médicamenteux , Lévofloxacine/usage thérapeutique , Maladies pulmonaires/traitement médicamenteux , Dermatoses bactériennes/traitement médicamenteux , Infections des tissus mous/traitement médicamenteux , Adulte , Antibactériens/administration et posologie , Antibactériens/effets indésirables , Bronchite/microbiologie , Relation dose-effet des médicaments , Femelle , Humains , Lévofloxacine/administration et posologie , Lévofloxacine/effets indésirables , Maladies pulmonaires/microbiologie , Mâle , Tests de sensibilité microbienne , Adulte d'âge moyen , Pneumopathie bactérienne/traitement médicamenteux , Pneumopathie bactérienne/microbiologie , Indice de gravité de la maladie , Dermatoses bactériennes/microbiologie , Infections des tissus mous/microbiologie , Résultat thérapeutique , Tuberculose pulmonaire/traitement médicamenteux , Tuberculose pulmonaire/microbiologie , Jeune adulteRÉSUMÉ
Clinical and microbiological efficacy of Cifran OD (Ranbaxy, India), a formulation with prolonged action and extended release of ciprofloxacin was studied in 22 patients with bacteriuria and lingering diabetes mellitus. Ciprofloxacin was used in doses of 500 or 1000 mg orally once a day depending on the severity of the disease singns for 2-3 weeks as etiotropic therapy and only in 2 cases with severe pyelonephritis it was used intravenously drop-wise and orally simultaneously. Twenty eight microbial strains isolated from urea of the patients were tested. The main species of the isolates belonged to the family Enterobacteriaceae. Twenty five isolates (89.3%) were susceptible to ciprofloxacin and 3 isolates (10.7%) were resistant. The clinical efficacy of ciprofloxacin was 90.9%.
Sujet(s)
Complications du diabète/traitement médicamenteux , Fluoroquinolones/usage thérapeutique , Infections urinaires/traitement médicamenteux , Administration par voie orale , Adulte , Sujet âgé , Sujet âgé de 80 ans ou plus , Ciprofloxacine/analogues et dérivés , Préparations à action retardée/administration et posologie , Préparations à action retardée/usage thérapeutique , Enterobacteriaceae/effets des médicaments et des substances chimiques , Enterobacteriaceae/isolement et purification , Femelle , Fluoroquinolones/administration et posologie , Humains , Mâle , Adulte d'âge moyenRÉSUMÉ
Autoantibodies to cell surface antigens of human somatotropinoma (ASAS), human prolactinoma (ASAP) and rat adenohypophysis (ASARA) were assayed in the serum of patients with pituitary diseases associated with GH deficiency (GHD), such as pituitary dwarfism and primary empty sella syndrome (ESS), and in the serum of patients with hyperprolactinaemia of different etiologies: idiopathic hyperprolactinaemia, prolactinoma and ESS. The investigation was carried out with a cellular variant of an ELISA. Among children with GHD, the highest percentage of antibody-positive patients was found in the group with idiopathic isolated GHD (89% of ASAS(+) patients and 30% of ASARA(+) patients vs 33.3% and 0% respectively in the group with idiopathic combined pituitary hormone deficiency, and 33.3% and 9% in patients with pituitary hypoplasia associated with isolated GHD or combined pituitary hormone deficiency). Among hyperprolactinaemic patients, the highest ASAP and ASARA frequency was observed in patients with idiopathic hyperprolactinaemia (67.7% and 41.9% respectively) where it was twice as high as in the group of patients with prolactinoma. The proportion of ASAS(+) and ASARA(+) did not differ significantly between the groups of patients with ess with or without GHD. Similarly, there was no significant difference between the number of ESS ASAP(+) and ASARA(+) patients with or without hyperprolactinaemia. The data obtained suggested that autoimmune disorders may be primary, and responsible, at least in part, for pituitary dysfunction in the cases of idiopathic isolated GHD and idiopathic hyperprolactinaemia. At the same time, the autoimmune disorders in the patients with prolactinoma or ESS are probably secondary to the organic pituitary lesion and their significance in the development of the pituitary dysfunction is obscure.